August 21, 2017

SWHR Lauds Passage and Signage of FDA Reauthorization Act of 2017 into Law

On August 21, 2017, the Society for Women’s Health Research President and CEO Amy M. Miller issued the following statement:

“The Society for Women’s Health Research (SWHR®) congratulates the Congress for passing and the President for signing the Food and Drug Administration (FDA) Reauthorization Act of 2017. By providing significant funding and important improvements to FDA’s medical products review and approval process, this law will enable timely access to safe and effective medical innovations to millions of patients who need them. SWHR applauds the law’s emphasis on integrating a patient’s perspective into the drug and device development process, and supporting the use of real-world evidence in 21st century regulatory science.”

“SWHR commends Congress for making the reauthorization of the user fee agreements a legislative priority, and for moving forward with its timely completion and unimpeded passage,” said Dr. Miller. “Ensuring the availability of safe and effective medical products is essential to women living longer, healthier, more productive lives.”

“SWHR looks forward to working with the FDA and the Administration to implement this foundational law,” said Dr. Miller.

About SWHR
The Society for Women’s Health Research (SWHR®) is a national non-profit based in Washington, DC. A thought-leader in promoting research on biological differences in disease, SWHR is dedicated to advancing women’s health through science, advocacy, and education. Top of FormFounded in 1990 by a group of physicians, medical researchers, and health advocates, SWHR brings attention to the variety of diseases and conditions that disproportionately or predominately affect women.